KemPharm is planning to initiate the development of KP511, an oral prodrug of hydromorphone that is used to manage pain in patients where an opioid analgesic is appropriate.

The drug candidate, which was identified using the Ligand Activated Therapy (LAT) approach, is the second product in the company’s pain therapy range.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

KP511 has demonstrated superior pharmacological characteristics, an improved safety profile and reduced symptoms of constipation, and has limited abuse potential in preclinical studies.

The drug candidate also has tamper-resistant properties, the company said.

KemPharm CEO Travis Mickle said the company aims to develop prescription options to enable physicians to treat pain without the liabilities of drug abuse and diversion or the negative side effect of constipation, which is typically associated with opioids.

 

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

Clinical Trials Arena Excellence Awards - Nominations Closed

Nominations are now closed for the Clinical Trials Arena Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact.

Excellence in Action
Recognised with 2025 Excellence Awards for Research and Development and Marketing , Novotech converted FDA/EMA fast track designations into faster HDV trial timelines while translating complex HBV science into sponsor ready insights. Discover how this dual strength in execution and communication is reshaping liver disease clinical development.

Discover the Impact